MOUNTAIN VIEW, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 2014 Stifel Healthcare Conference on Wednesday, November 19, 2014, at 8:00 a.m. Eastern Time at The Palace Hotel in New York, NY. Dr. Schall will also present at the Goldman Sachs U.S. Emerging / SMID CAP Growth Conference on Thursday, November 20, 2014, at 10:50 a.m. Eastern Time at the New York Marriott Marquis in New York, NY.
Live audio webcasts of the presentations can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. Replays of the webcasts will be available on the Company’s website for two weeks following the live presentations.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. Other clinical programs include CCX872, a next generation CCR2 inhibitor currently in Phase I clinical development, CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.
CCXI - G
CONTACT: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer or Markus J. Cappel, Ph.D. Chief Business Officer 650.210.2900 investor@chemocentryx.com Media: Denise Powell 510.703.9491 denise@redhousecomms.com Investors: Angeli Kolhatkar Burns McClellan 212.213.0006 akolhatkar@burnsmc.com
Help employers find you! Check out all the jobs and post your resume.
